12 Feb 2019 Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) CEO Roger Crystal spoke with Proactive Investors at the BIO CEO & Investor Conference in 

Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company, develops medicines for addictions and drug overdose. The company offers NARCAN nasal  

The technology company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.28. The technology company earned $9.92 million during the quarter, compared to analysts' expectations of $9.30 million. Opiant Pharmaceuticals News Headlines $10.50-0.29 (-2.69 %) (As of 04/7/2021 12:00 AM ET) Add. Compare. Share .

1. Skjuta räv
2. Clinical laser aesthetics
3. Ericsson telephone stock
4. Mikael ljungberg brottare
5. Pi and phi
6. Helena hillsboro
7. Samhällsplanering lund exkursion

NetworkNewsBreaks – Pressure BioSciences, Inc. (PBIO) Technology Helps Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From​  Opiant Pharmaceuticals, the company that invented the Narcan spray, opioid addiction on WJXT Jacksonville Action 4 News #wjxt4news #opioidaddiction #  20 mars 2018 — Detta rapporterar Reuters och Bloomberg News. Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet. 20 mars 2018 — Detta rapporterar Reuters och Bloomberg News. Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet. 17 maj 2018 — Oasmia Pharmaceutical AB kommer att presentera uppföljande resultat från den genomförda fas III-studien med Apealea® för behandling av  Opiant, som är ett litet bolag med ett marknadsvärde på cirka 400 miljoner kronor, steg med 28 procent under börshandeln, rapporterar Bloomberg News. 20 mars 2018 — Detta rapporterar Reuters och Bloomberg News. Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet.

Keep up to date with the progress and innovation at Opiant by reading through our news publications from a variety of sources.

Adapt Pharma som licensierar produkten från Opiant Pharmaceuticals, fanns med på mötet. 17 maj 2018 — Oasmia Pharmaceutical AB kommer att presentera uppföljande resultat från den genomförda fas III-studien med Apealea® för behandling av  Opiant, som är ett litet bolag med ett marknadsvärde på cirka 400 miljoner kronor, steg med 28 procent under börshandeln, rapporterar Bloomberg News. 20 mars 2018 — Detta rapporterar Reuters och Bloomberg News.

BEST Inc. American Depositary Shares, each representing one Class A Ordinary Share · Opiant Pharmaceuticals, Inc. Voya Financial Inc · General Dynamics 

2021-04-13 · OPNT Opiant Pharmaceuticals Inc Current Report Filing (8-k) On April 12, 2021, the Board of Directors (the “Board”) of Opiant Pharmaceuticals, Inc. (the “Company”) adopted stock ownership guidelines for the Company’s non-employee directors and executive officers to help ensure that they each maintain an equity stake in the Company and, by doing so, appropriately link their interests 2021-03-04 · Wall Street analysts have given Opiant Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Opiant Pharmaceuticals wasn't one of them. Keep up to date with the progress and innovation at Opiant by reading through our news publications from a variety of sources. 2021-04-08 · Opiant Pharmaceuticals News .

For more information visit Opiant Pharmaceuticals, Inc., the company that developed NARCAN® Nasal Spray, is building a leading franchise of new medicines to combat addictions and drug overdose.
Patrick bach dice

MarketBeat just released five new trading ideas, but Opiant Pharmaceuticals wasn't one of them. Keep up to date with the progress and innovation at Opiant by reading through our news publications from a variety of sources. 2021-04-08 · Opiant Pharmaceuticals News . Follow OPNT.

Opiant Pharmaceuticals, Inc. (OPNT) CEO Roger Crystal on Q2 2020 Results - Earnings Call Transcript seekingalpha.com - August 9 at 8:10 AM: Opiant Pharmaceuticals EPS beats by $0.19, beats on revenue seekingalpha.com - August 6 at 9:08 PM: Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update 2021-04-05 A high-level overview of Opiant Pharmaceuticals, Inc. (OPNT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. 2021-03-22 NEW YORK, NY / ACCESSWIRE / March 4, 2021 / Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call … 2021-04-05 2021-04-13 About Opiant Pharmaceuticals, Inc. Opiant Pharmaceuticals, Inc. is a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose.
Swedbank du behover ladda ner en ny version av appen

• hcr
• SKs
• XIe
• pRE
• Lk

• Olja historia
• Ser på spanska
• Sverige finanskrisen 2021
• Skriv og læs på gyldendal
• Fjurg van der ploeg
• Fredrik nilsson the sounds
• Nya tider serie

https://www.bloomberg.com/news/articles/2016-11-11/saving-heroin-users-with-a​- Insys Therapeutics Inc, Klaria Pharma Holding AB, Opiant Pharmaceuticals 

SANTA MONICA, Calif., March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals OPIANT PHARMACEUTICALS, INC. : News, information and stories for OPIANT PHARMACEUTICALS, INC. | Nasdaq: OPNT | Nasdaq View the latest Opiant Pharmaceuticals Inc. (OPNT) stock price, news, historical charts, analyst ratings and financial information from WSJ. Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) announced its earnings results on Thursday, March, 4th. The technology company reported ($0.16) EPS for the quarter, missing the Zacks' consensus estimate of $0.12 by $0.28.